Dibromodulcitol Therapeutic Efficacy via Parameter Changes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for cancer, such as dibromodulcitol and others, often exhibit suboptimal performance due to limitations in efficacy and severe side effects, leading to disappointing results in clinical trials and limited clinical utility, necessitating the development of improved compositions and methods to enhance their therapeutic benefit.
Innovation Solution
The development of novel compositions and methods that include dose modifications, alternative routes of administration, combination therapies, pharmacokinetic monitoring, and the use of diagnostic kits to identify suitable patients, along with the incorporation of drug delivery systems and prodrugs, aims to improve the efficacy and reduce side effects of suboptimally administered chemical compounds like dibromodulcitol and other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic agents like dibromodulcitol are administered at standard doses, then they can treat cancer, but they cause severe side effects and exhibit suboptimal efficacy
Solution Approach 1:
The patent applies parameter changes by modifying the dosing regimen (frequency, duration, amount) and administration route of dibromodulcitol to optimize therapeutic efficacy while reducing side effects. This involves changing the parameters of drug delivery to achieve better clinical outcomes without the severe toxicities associated with conventional dosing.
Solution Approach 2:
The patent employs preliminary action through the use of diagnostic kits and biomarker analysis before administering therapy. This allows for patient selection and treatment planning that anticipates and prevents adverse reactions, ensuring that only suitable patients receive the therapy and that dosing is optimized in advance to minimize side effects.
2Measurement precision
If diagnostic kits and biomarker analysis are used to identify suitable patients, then patient selection is improved, but the complexity of the treatment protocol increases
Solution Approach 1:
The diagnostic kits and biomarker analysis are performed in advance before treatment initiation. This preliminary action allows for accurate patient selection and treatment planning to be completed beforehand, reducing the need for complex monitoring and adjustments during the actual treatment phase.
Solution Approach 2:
The diagnostic kits are designed to be relatively simple and self-contained, allowing for straightforward administration and interpretation. The biomarkers naturally indicate patient suitability without requiring complex external validation, enabling the system to self-determine patient eligibility through measurable biological markers.
3Reliability
If dose modifications and alternative administration routes are implemented, then therapeutic benefit is enhanced, but the manufacturing and administration complexity increases
Solution Approach 1:
The patent modifies dosing parameters (amount, frequency, duration) and administration routes to enhance therapeutic benefit. These parameter changes are implemented through standardized dosage forms and protocols that, while varied, maintain manufacturing feasibility through established pharmaceutical processes.
Data Source
AI summary
The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to substituted hexitols such as dibromodulcitol or analogs, derivatives, or prodrugs thereof.